<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Anesthesiology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/anesthesiology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>New data support the efficacy of paracervical block for induced abortion</title>
		<link>http://www.thedoctorschannel.com/view/new-data-support-the-efficacy-of-paracervical-block-for-induced-abortion/</link>
		<pubDate>Fri, 27 Apr 2012 18:22:59 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[abortion]]></category>
		<category><![CDATA[Paracervical block]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30264</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Paracervical block is effective in decreasing pain associated with first-trimester surgical abortion, suggest results of a randomized controlled trial conducted in Portland, Oregon. In the May issue of Obstetrics &#038; Gynecology, available online now, the study team notes that most first-trimester surgical abortions are performed with a paracervical block. But -]]></description>
		
			<media:content duration="1:39" medium="video">
		<media:title><![CDATA[New data support the efficacy of paracervical block for induced abortion]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Paracervical block is effective in decreasing pain associated with first-trimester surgical abortion, suggest results of a randomized controlled trial conducted in Portland, Oregon. In the May issue of Obstetrics &#038; Gynecology, available online now, the study team notes that most first-trimester surgical abortions are performed with a paracervical block. But -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/new-data-support-the-efficacy-of-paracervical-block-for-induced-abortion/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120427clin0012.jpg"/>
	<media:keywords><![CDATA[abortion,Paracervical block]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Zoledronic acid lacks antitumor effect in metastatic breast cancer</title>
		<link>http://www.thedoctorschannel.com/view/zoledronic-acid-lacks-antitumor-effect-in-metastatic-breast-cancer-7/</link>
		<pubDate>Mon, 19 Dec 2011 14:26:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[bisphosphonate]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[zoledronic acid]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/zoledronic-acid-lacks-antitumor-effect-in-metastatic-breast-cancer-7/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – For women with breast cancer metastatic to bone, treatment with zoledronic acid to reduce skeletal complications does not prolong progression-free survival or overall survival, according to the results of a retrospective study reported in Cancer online December 2nd. “In patients with bone-only metastasis, we could not demonstrate antitumor effects of -]]></description>
		
			<media:content duration="1:33" medium="video">
		<media:title><![CDATA[Zoledronic acid lacks antitumor effect in metastatic breast cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – For women with breast cancer metastatic to bone, treatment with zoledronic acid to reduce skeletal complications does not prolong progression-free survival or overall survival, according to the results of a retrospective study reported in Cancer online December 2nd. “In patients with bone-only metastasis, we could not demonstrate antitumor effects of -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/zoledronic-acid-lacks-antitumor-effect-in-metastatic-breast-cancer-7/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4942.jpg"/>
	<media:keywords><![CDATA[bisphosphonate,breast cancer,oncology,zoledronic acid]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Oral azithromycin superior to topical tetracycline after trichiasis surgery</title>
		<link>http://www.thedoctorschannel.com/view/oral-azithromycin-superior-to-topical-tetracycline-after-trichiasis-surgery-2/</link>
		<pubDate>Thu, 15 Dec 2011 20:47:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[azithromycin]]></category>
		<category><![CDATA[ophthalmology]]></category>
		<category><![CDATA[surgery]]></category>
		<category><![CDATA[topical tetracycline]]></category>
		<category><![CDATA[Trichiasis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/oral-azithromycin-superior-to-topical-tetracycline-after-trichiasis-surgery-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A single dose of oral azithromycin reduces the recurrence of trichiasis for up to three years more so than a six-week regimen of topical tetracycline, researchers report. This strategy “fits” with the World Health Organization&#8217;s multifaceted strategy for eliminating trachoma by 2020, Dr. Sheila West, of the Dana Center for -]]></description>
		
			<media:content duration="1:29" medium="video">
		<media:title><![CDATA[Oral azithromycin superior to topical tetracycline after trichiasis surgery]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A single dose of oral azithromycin reduces the recurrence of trichiasis for up to three years more so than a six-week regimen of topical tetracycline, researchers report. This strategy “fits” with the World Health Organization&#8217;s multifaceted strategy for eliminating trachoma by 2020, Dr. Sheila West, of the Dana Center for -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/oral-azithromycin-superior-to-topical-tetracycline-after-trichiasis-surgery-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4935.jpg"/>
	<media:keywords><![CDATA[azithromycin,ophthalmology,surgery,topical tetracycline,Trichiasis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Pre-surgery chemo improves survival of early-stage lung cancer patients</title>
		<link>http://www.thedoctorschannel.com/view/pre-surgery-chemo-improves-survival-of-early-stage-lung-cancer-patients/</link>
		<pubDate>Mon, 05 Dec 2011 14:24:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[gemcitabine]]></category>
		<category><![CDATA[non-small-cell lung cancer]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[surgery]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/pre-surgery-chemo-improves-survival-of-early-stage-lung-cancer-patients/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Among patients with early stage non-small-cell lung cancer, treatment with gemcitabine and cisplatin before radical surgery is associated with better survival than is surgery alone, according to a European study reported in the Journal of Clinical Oncology online. “This prematurely closed phase III study indicates estimates of efficacy outcome in -]]></description>
		
			<media:content duration="1:55" medium="video">
		<media:title><![CDATA[Pre-surgery chemo improves survival of early-stage lung cancer patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Among patients with early stage non-small-cell lung cancer, treatment with gemcitabine and cisplatin before radical surgery is associated with better survival than is surgery alone, according to a European study reported in the Journal of Clinical Oncology online. “This prematurely closed phase III study indicates estimates of efficacy outcome in -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/pre-surgery-chemo-improves-survival-of-early-stage-lung-cancer-patients/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4904.jpg"/>
	<media:keywords><![CDATA[chemotherapy,cisplatin,gemcitabine,non-small-cell lung cancer,NSCLC,oncology,surgery]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Zoledronic acid maintains BMD in breast cancer patients on letrozole</title>
		<link>http://www.thedoctorschannel.com/view/zoledronic-acid-maintains-bmd-in-breast-cancer-patients-on-letrozole/</link>
		<pubDate>Wed, 23 Nov 2011 22:38:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[bone loss]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[letrozole]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[womens health]]></category>
		<category><![CDATA[zoledronic acid]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/zoledronic-acid-maintains-bmd-in-breast-cancer-patients-on-letrozole/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Bone loss in postmenopausal women taking adjuvant letrozole for early breast cancer can be prevented with administration of zoledronic acid, investigators report in Cancer online October 10. Nonetheless, they advise, “The results from other ongoing clinical trials (eg, Southwest Oncology Group S0307) evaluating disease-free survival in breast cancer patients receiving -]]></description>
		
			<media:content duration="1:49" medium="video">
		<media:title><![CDATA[Zoledronic acid maintains BMD in breast cancer patients on letrozole]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Bone loss in postmenopausal women taking adjuvant letrozole for early breast cancer can be prevented with administration of zoledronic acid, investigators report in Cancer online October 10. Nonetheless, they advise, “The results from other ongoing clinical trials (eg, Southwest Oncology Group S0307) evaluating disease-free survival in breast cancer patients receiving -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/zoledronic-acid-maintains-bmd-in-breast-cancer-patients-on-letrozole/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4845.jpg"/>
	<media:keywords><![CDATA[bone loss,cancer,letrozole,oncology,womens health,zoledronic acid]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Older age not a barrier to hematopoietic cell transplantation for blood cancer</title>
		<link>http://www.thedoctorschannel.com/view/older-age-not-a-barrier-to-hematopoietic-cell-transplantation-for-blood-cancer/</link>
		<pubDate>Fri, 04 Nov 2011 20:28:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[comorbid conditions]]></category>
		<category><![CDATA[geriatrics]]></category>
		<category><![CDATA[HCT]]></category>
		<category><![CDATA[hematologic malignancies]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/older-age-not-a-barrier-to-hematopoietic-cell-transplantation-for-blood-cancer/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Older patients with advanced hematologic malignancies and comorbid conditions can successfully undergo nonmyeloablative allogeneic hematopoietic cell transplantation (HCT), results of a new study show. With the advent of non-myeloablative conditioning regimens, “the notion that hematopoietic cell transplantation is too toxic for the older population with advanced hematologic malignancies is no -]]></description>
		
			<media:content duration="1:49" medium="video">
		<media:title><![CDATA[Older age not a barrier to hematopoietic cell transplantation for blood cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Older patients with advanced hematologic malignancies and comorbid conditions can successfully undergo nonmyeloablative allogeneic hematopoietic cell transplantation (HCT), results of a new study show. With the advent of non-myeloablative conditioning regimens, “the notion that hematopoietic cell transplantation is too toxic for the older population with advanced hematologic malignancies is no -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/older-age-not-a-barrier-to-hematopoietic-cell-transplantation-for-blood-cancer/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4806.jpg"/>
	<media:keywords><![CDATA[comorbid conditions,geriatrics,HCT,hematologic malignancies]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Solid organ recipients at increased risk for a range of cancers</title>
		<link>http://www.thedoctorschannel.com/view/solid-organ-recipients-at-increased-risk-for-a-range-of-cancers/</link>
		<pubDate>Fri, 04 Nov 2011 20:21:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[National Cancer Institute]]></category>
		<category><![CDATA[organ transplatn]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/solid-organ-recipients-at-increased-risk-for-a-range-of-cancers/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – After organ transplantation, the overall risk of any new malignancy doubles, according to a new report from the U.S. National Cancer Institute. The NCI study, reported online today in the Journal of the American Medical Association, found that transplant recipients have an elevated risk of 32 different types of cancers, -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Solid organ recipients at increased risk for a range of cancers]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – After organ transplantation, the overall risk of any new malignancy doubles, according to a new report from the U.S. National Cancer Institute. The NCI study, reported online today in the Journal of the American Medical Association, found that transplant recipients have an elevated risk of 32 different types of cancers, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/solid-organ-recipients-at-increased-risk-for-a-range-of-cancers/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4805.jpg"/>
	<media:keywords><![CDATA[National Cancer Institute,organ transplatn]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Capecitabine improves survival in women with advanced breast cancer</title>
		<link>http://www.thedoctorschannel.com/view/capecitabine-improves-survival-in-women-with-advanced-breast-cancer/</link>
		<pubDate>Thu, 03 Nov 2011 18:58:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[capecitabine]]></category>
		<category><![CDATA[CMF]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<category><![CDATA[womens health]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/capecitabine-improves-survival-in-women-with-advanced-breast-cancer/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – For women with advanced breast cancer, capecitabine provides similar overall survival with less toxicity compared with classical cyclophosphamide, methotrexate, and fluorouracil (CMF) first-line therapy, researchers report in the October 24th online Journal of Clinical Oncology. “Single agent capecitabine is a good option as first line chemotherapy for the many women -]]></description>
		
			<media:content duration="1:35" medium="video">
		<media:title><![CDATA[Capecitabine improves survival in women with advanced breast cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – For women with advanced breast cancer, capecitabine provides similar overall survival with less toxicity compared with classical cyclophosphamide, methotrexate, and fluorouracil (CMF) first-line therapy, researchers report in the October 24th online Journal of Clinical Oncology. “Single agent capecitabine is a good option as first line chemotherapy for the many women -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/capecitabine-improves-survival-in-women-with-advanced-breast-cancer/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4802.jpg"/>
	<media:keywords><![CDATA[breast cancer,capecitabine,CMF,Journal of Clinical Oncology,womens health]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Nail bed hemorrhage associated with optic disc hemorrhage in glaucoma</title>
		<link>http://www.thedoctorschannel.com/view/nail-bed-hemorrhage-associated-with-optic-disc-hemorrhage-in-glaucoma/</link>
		<pubDate>Wed, 02 Nov 2011 22:31:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[disc hemorrhage]]></category>
		<category><![CDATA[nail bed hemorrhage]]></category>
		<category><![CDATA[retinal nerve fiber]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/nail-bed-hemorrhage-associated-with-optic-disc-hemorrhage-in-glaucoma/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Nail bed hemorrhage may serve as a clinical marker of optic disc hemorrhage in patients with glaucoma, researchers from South Korea report in the October Archives of Ophthalmology. Nailfold capillaroscopy is a simple, safe, noninvasive, and inexpensive technique for studying the microcirculation in vivo. In ophthalmology, it has been used -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Nail bed hemorrhage associated with optic disc hemorrhage in glaucoma]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Nail bed hemorrhage may serve as a clinical marker of optic disc hemorrhage in patients with glaucoma, researchers from South Korea report in the October Archives of Ophthalmology. Nailfold capillaroscopy is a simple, safe, noninvasive, and inexpensive technique for studying the microcirculation in vivo. In ophthalmology, it has been used -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/nail-bed-hemorrhage-associated-with-optic-disc-hemorrhage-in-glaucoma/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4799.jpg"/>
	<media:keywords><![CDATA[disc hemorrhage,nail bed hemorrhage,retinal nerve fiber]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>The Cancer Foundation for Personal Appearance &#8211; 10th Anniversary Celebration</title>
		<link>http://www.thedoctorschannel.com/view/the-cancer-foundation-for-personal-appearance-10th-anniversary-celebration/</link>
		<pubDate>Wed, 02 Nov 2011 14:35:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Doc Life]]></category>
		<category><![CDATA[Cancer Foundation for Personal Appearance]]></category>
		<category><![CDATA[Cherry Hill]]></category>
		<category><![CDATA[Joe Minniti]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/the-cancer-foundation-for-personal-appearance-10th-anniversary-celebration/</guid>
		<description><![CDATA[The Cancer Foundation for Personal Appearance celebrates its 10th Anniversary! Congratulations to Joseph Minniti, Founder and Director, and to everyone at the foundation who has made a difference in the lives of so many. For more information, please visit The Cancer Foundation for Personal Appearance]]></description>
		
			<media:content duration="2:18" medium="video">
		<media:title><![CDATA[The Cancer Foundation for Personal Appearance &#8211; 10th Anniversary Celebration]]></media:title>
	<media:description><![CDATA[The Cancer Foundation for Personal Appearance celebrates its 10th Anniversary! Congratulations to Joseph Minniti, Founder and Director, and to everyone at the foundation who has made a difference in the lives of so many. For more information, please visit The Cancer Foundation for Personal Appearance]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/the-cancer-foundation-for-personal-appearance-10th-anniversary-celebration/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4797.jpg"/>
	<media:keywords><![CDATA[Cancer Foundation for Personal Appearance,Cherry Hill,Joe Minniti]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
